Abstract
The diagnosis of well-differentiated thyroid cancers, which constitute the majority of pediatric thyroid malignancies, relies on neck ultrasonography (US) and fine-needle aspiration biopsy (FNAB). Thyroid scintigraphy has a limited role at this stage. Based on US and FNAB findings—with molecular tests, if possible—the surgical approach is determined. In some cases, additional cross-sectional imaging may be required for preoperative evaluation. Postoperatively, the patient is referred to Nuclear Medicine for consideration of radioactive iodine (RAI) therapy. The presence of residual thyroid tissue is assessed using thyroid scintigraphy (Tc-99m pertechnetate, I-123 or I-131). Radioiodine imaging also allows for whole-body scanning. Cervical lymph nodes are evaluated with neck US. If surgically resectable residual cervical metastatic disease is detected, reoperation should be considered before RAI therapy. Serum thyroid-stimulating hormone (TSH), thyroglobulin (Tg), and anti-Tg antibody levels should be measured. Elevated Tg levels raise suspicion for distant metastases, particularly in the lungs, and warrant evaluation with non-contrast chest computed tomography. Pathology findings—including tumor subtype, invasive features, and the location and number of metastatic lymph nodes—are integrated to determine the patient’s risk category. RAI therapy is not recommended for low risk patients. When indicated, I-131 activity is generally administered empirically, with adult doses adjusted for the pediatric population. All patients should undergo follow-up with TSH suppression. Recurrence most commonly occurs in cervical lymph nodes, while persistent distant metastases are most often observed in the lungs. Management may include reoperation, additional RAI therapy or TSH suppression on a case-by-case basis. Although RAI refractory disease is rare in children, systemic therapies—either for therapeutic or redifferentiation purposes—should be considered when there is clinically significant progression that cannot be controlled with local treatments.
Keywords: Thyroid neoplasms, child, neck ultrasonography, radioiodine therapy, thyroglobulin
References
National Cancer Institute Surveillance, Epidemiology, and End Results Program. Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2022 [Available from: https://seer.cancer.gov/statistics-network/explorer/application.html?site=80&data_type=1&graph_type=2&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=15&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=1.
Cherella CE, Wassner AJ. Pediatric thyroid cancer: recent developments. Best Pract Res Clin Endocrinol Metab. 2023;37:101715.
Faquinj W BA, Aga M, Rossi E. Who classification of tumours series. 5th ed. International Agency for Research on Cancer, 2022.
Lai ST, Bauer AJ. Approach to the pediatric patient with thyroid nodules. J Clin Endocrinol Metab. 2025;110:2339-2352.
Collini P, Mattavelli F, Pellegrinelli A, Barisella M, Ferrari A, Massimino M. Papillary carcinoma of the thyroid gland of childhood and adolescence: morphologic subtypes, biologic behavior and prognosis: a clinicopathologic study of 42 sporadic cases treated at a single institution during a 30-year period. Am J Surg Pathol. 2006;30:1420-6.
Halada S, Baran JA, Bauer AJ, et al. Clinicopathologic characteristics of pediatric follicular variant of papillary thyroid carcinoma subtypes: a retrospective cohort study. Thyroid. 2022;32:1353-1361.
Enomoto K, Enomoto Y, Uchino S, Yamashita H, Noguchi S. Follicular thyroid cancer in children and adolescents: clinicopathologic features, long-term survival, and risk factors for recurrence. Endocr J. 2013;60:629-635.
Yamashita S, Saenko V. Mechanisms of disease: molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007;3:422-429.
Paulson VA, Rudzinski ER, Hawkins DS. Thyroid cancer in the pediatric population. Genes. 2019;10:723.
Gallant JN, Chen SC, Ortega CA, et al. Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children. JAMA Oncol. 2022;8:1323-1327.
Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on pediatric thyroid cancer. Thyroid. 2015;25:716-759.
Gupta A, Ly S, Castroneves LA, et al. A standardized assessment of thyroid nodules in children confirms higher cancer prevalence than in adults. J Clin Endocrinol Metab. 2013;98:3238-3245.
Parisi MT, Eslamy H, Mankoff D. Management of differentiated thyroid cancer in children: focus on the American Thyroid Association Pediatric Guidelines. Semin Nucl Med. 2016;46:147-164.
Niedziela M, Breborowicz D, Trejster E, Korman E. Hot nodules in children and adolescents in western Poland from 1996 to 2000: clinical analysis of 31 patients. J Pediatr Endocrinol Metab. 2002;15:823-830.
Lebbink CA, Links TP, Czarniecka A, et al. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022;11: e220146.
Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS committee. J Am Coll Radiol. 2017;14:587-595.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
Borysewicz-Sańczyk H, Sawicka B, Karny A, et al. Suspected malignant thyroid nodules in children and adolescents according to ultrasound elastography and ultrasound-based risk stratification systems—experience from one center. J Clin Med. 2022;11:1768.
Yeh MW, Bauer AJ, Bernet VA, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid. 2015;25:3-14.
Srivatsa S, Al-Hadidi A, Stanek J, et al. Assessing the diagnostic accuracy of TI-RADS in pediatric thyroid nodules: a multiinstitutional review. J Pediatr Surg. 2025;60:161924.
Lee JY, Shin JH, Han B-K, et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid: imaging and cytologic findings. Thyroid. 2007;17:567-573.
Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda system for reporting thyroid cytopathology. Thyroid. 2023;33:1039-1044.
Baloch ZW, LiVolsi VA. Post fine-needle aspiration histologic alterations of thyroid revisited. Am J Clin Pathol. 1999;112:311-316.
Stack Jr BC, Twining C, Rastatter J, et al. Consensus statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section (AHNS‐ES) on pediatric benign and malignant thyroid surgery. Head Neck. 2021;43:1027-1042.
Dionigi G, Kraimps J-L, Schmid KW, et al. Minimally invasive follicular thyroid cancer (MIFTC)—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399:165-184.
Sugino K, Ito K, Nagahama M, et al. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid. 2011;21:751-757.
Buryk MA, Monaco SE, Witchel SF, et al. Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules. Int J Pediatr Otorhinolaryngol. 2013;77:1697-1700.
Monaco SE, Pantanowitz L, Khalbuss WE, et al. Cytomorphological and molecular genetic findings in pediatric thyroid fine‐needle aspiration. Cancer Cytopathol. 2012;120:342-350.
Bauer AJ. Molecular genetics of thyroid cancer in children and adolescents. Endocrinol Metab Clin North Am. 2017;46:389-403.
Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol. 2019;5:204-212.
Sugino K, Nagahama M, Kitagawa W, et al. Risk stratification of pediatric patients with differentiated thyroid cancer: is total thyroidectomy necessary for patients at any risk? Thyroid. 2020;30:548-556.
Kiratli PÖ, Tuncel M, Bar-Sever Z. Nuclear medicine in pediatric and adolescent tumors. Semin Nucl Med. 2016;46:308-323.
Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005;12:773-803.
Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): what changed and why? Thyroid. 2017;27:751-756.
Bauer AJ. Pediatric thyroid cancer: genetics, therapeutics and outcome. Endocrinol Metab Clin North Am. 2020;49:589-611.
Jain NK, Mostoufi-Moab S, Hawkes CP, et al. Extrathyroidal extension is an important predictor of regional lymph node metastasis in pediatric differentiated thyroid cancer. Thyroid. 2020;30:1037-1043.
Jeon MJ, Kim YN, Sung T-Y, et al. Practical initial risk stratification based on lymph node metastases in pediatric and adolescent differentiated thyroid cancer. Thyroid. 2018;28:193-200.
Luster M, Pfestroff A, Hänscheid H, Verburg FA. Radioiodine therapy. Semin Nucl Med. 2017;47:126-134.
Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg. 2010;34:1192-1202.
Chow SM, Law SC, Mendenhall WM, et al. Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer. 2004;42:176-183.
Brink JS, Van Heerden JA, McIver B, et al. Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery. 2000;128:881-887.
Lee JI, Chung YJ, Cho BY, Chong S, Seok JW, Park SJ. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. Surgery. 2013;153:828-835.
Pluijmen MJ, Eustatia‐Rutten C, Goslings BM, et al. Effects of low‐iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2003;58:428-435.
Luster M, Handkiewicz-Junak D, Grossi A, et al. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab. 2009;94:3948-3953.
Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648-654.
Ledwon A, Paliczka-Cieślik E, Syguła A, et al. Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer. Ann Nucl Med. 2021;35:1214-1222.
Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265-271.
Jentzen W, Balschuweit D, Schmitz J, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging. 2010;37:2298-2306.
Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med. 2005;46:261-266.
Verburg FA, Hänscheid H, Biko J, et al. Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2010;37:896-903.
Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010;8:1277-1287.
Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J. 2002;78:92-93.
Smith MB, Xue H, Takahashi H, Cangir A, Andrassy RJ. Iodine 131 thyroid ablation in female children and adolescents: long-term risk of infertility and birth defects. Ann Surg Oncol. 1994;1:128-131.
Sawka AM, Lea J, Alshehri B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol (Oxf). 2008;68:610-617.
Rubino C, De Vathaire F, Dottorini M, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638-1644.
Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504-515.
Hurley JR. Historical note: TSH suppression for thyroid cancer. Thyroid. 2011;21:1175-1176.
Verburg FA, Luster M, Cupini C, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid. 2013;23:1211-1225.
Çetin SK, Aycan Z, Şıklar Z, et al. Clinical characteristics, risk stratifications, and long-term follow-up of childhood differentiated thyroid cancer: a single-center experience. Ann Pediatr Endocrinol Metab. 2025;30:86-94.
Zanella AB, Scheffel RS, Nava CF, et al. Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer. Thyroid. 2018;28:1285-1292.
Sung TY, Jeon MJ, Lee YH, et al. Initial and dynamic risk stratification of pediatric patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2017;102:793-800.
Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah B. Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following 131I treatment: a systematic review. Thyroid. 2010;20:1095-1101.
Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, Drozd V. Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur J Nucl Med Mol Imaging. 2011;38:651-655.
Padovani RP, Robenshtok E, Brokhin M, Tuttle RM. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid. 2012;22:778-783.
Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29:461-470.
Aashiq M, Silverman DA, Na’ara S, Takahashi H, Amit M. Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers (Basel). 2019;11:1382.
Mahajan P, Dawrant J, Kheradpour A, et al. Response to lenvatinib in children with papillary thyroid carcinoma. Thyroid. 2018;28:1450-1454.
Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid. 2009;19:407-412.
Lee YA, Lee H, Im SW, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest. 2021;131:e144847.
Waguespack SG, Tewari SO, Busaidy NL, Zafereo ME. Larotrectinib before initial radioactive iodine therapy in pediatric TRK fusion–positive papillary thyroid carcinoma: time to reconsider the treatment paradigm for distantly metastatic disease? JCO Precis Oncol. 2022;6:e2100467.
